Jun 15, 2020
Black Health Matters To Launch New Kidney Disease Channel
May 28, 2020
Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases
May 18, 2020
Global Focal Segmental Glomerulosclerosis (FSGS) Industry Report 2020 - Epidemiology, Pipeline, Drugs, KOL Views, Companies and Outlook to 2030
Jan 30, 2020
ZyVersa Therapeutics Featured in Business Worldwide Magazine's Winter Edition as One of the 20 Most Innovative Companies to Watch
Oct 21, 2019
Focal Segmental Glomerulosclerosis (FSGS) Market Insights, Epidemiology, and Market Forecasts, 2028
Sep 25, 2019
Interview with ZyVersa Therapeutics' CEO, Stephen C. Glover, Published in CEOCFO Magazine
May 01, 2019
Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.
Mar 08, 2019
NephCure Kidney International Announces Three New Scientific Advisory Board Members
Feb 19, 2019
NephCure Kidney International Launches Revolutionary Clinical Trial Discovery Tool For Kidney Diseases: KidneyHealthGateway.com
Jan 03, 2019
Data on Use of Mallinckrodt's H.P. Acthar® Gel (Repository Corticotropin Injection) in Patients with Rare Cause of Nephrotic Syndrome Published in Transplantation
Dec 03, 2018
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
Nov 02, 2018
American Kidney Fund's Most Visited Webpages Highlight Connection Between Protein in Urine and Chronic Kidney Disease
Nov 01, 2018
NephCure Kidney International's Annual Countdown to a Cure Gala in NYC on Track for Record-Breaking Year
Oct 30, 2018
Variant Pharmaceuticals Submits Application for U.S. Orphan Drug Designation for VAR 200 (2-Hydroxypropyl-b-Cyclodextrin) To Treat Focal Segmental Glomerulosclerosis (FSGS)
Oct 25, 2018
Experimental Drug More Effective in Treating Rare Kidney Disease
Oct 24, 2018
Variant Pharmaceuticals Announces Publication of Data Demonstrating 2-Hydroxypropyl-b-Cyclodextrin (2HPbCD) Protects Against Kidney Disease in Experimental Models of Alport Syndrome (AS) and Focal Segmental Glomerulosclerosis (FSGS)
Oct 16, 2018
Variant Pharmaceuticals Receives Notice of Allowance in Two U.S. Patent Applications Covering Lead Compound, 2-hydroxypropyl-b-cyclodextrin, a Phase 2a-ready Asset for Rare Renal Disease, Focal Segmental Glomerulosclerosis (FSGS)
Apr 16, 2018
Variant Pharmaceuticals Completes Pre-IND Meeting with FDA on VAR 200 for Focal Segmental Glomerulosclerosis (FSGS), a Rare Kidney Disease
Jan 24, 2018
Focal Segmental Glomerulosclerosis Market to Reach US$15.83 Billion by 2025, Globally: Transparency Market Research
Nov 06, 2017
NephCure Kidney International® Holds Countdown to a Cure Gala in NYC